Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
The source age scope and maximum-dose formulation are historical and separately retained, not silently expanded to newer indications.
Check source scope before reading a dose
GlobalRPh RX List - Vimpat
Product / population
VIMPAT renal maximum and hemodialysis instructions; adult and pediatric renal methods differ.
Source revision date not established in selected retrieval.
Retrieved
2026-09-07
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
Reduce the maximum, not automatically every established dose
VIMPAT specifies a reduction in the maximum permitted dose in severe impairment, alongside separate titration and post-HD considerations. It also uses different adult and pediatric renal-function methods.
What to reconcile: Distinguish a maximum-dose ceiling from a mandatory reduction of an already lower dose. Verify adult Cockcroft-Gault versus pediatric Schwartz units, current regimen, dialysis duration and interactions.
GlobalRPh-hosted RX List · VIMPAT renal maximum and hemodialysis instructions; adult and pediatric renal methods differ.
Renal method: Adults: Cockcroft-Gault CrCl below 30 mL/min. Pediatrics: Schwartz CLcr below 30 mL/min/1.73 m2. Source date: Source revision date not established in selected retrieval. Retrieved: 2026-09-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
Mild or moderate renal impairment needs no adjustment. For severe impairment or ESRD, reduce the maximum permitted dose by 25% and titrate cautiously to response and tolerability. This is a reduction in the maximum, not necessarily a mandatory 25% decrease in every existing dose. After four-hour hemodialysis, consider a supplement of up to 50%. Strong CYP3A4 or CYP2C9 inhibitors can require further reduction in renal impairment. Do not interchange the adult unindexed and pediatric indexed renal estimates.
RDM40-rxlist-lacosamide-8bd4a1d808-C1 · Source locator: Selected renal dosing, renal impairment, toxicity and pharmacokinetic subsections as identified in the summary.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.